Edwards Lifesciences (EW) Expected to Announce Earnings on Thursday

Edwards Lifesciences (NYSE:EW) is projected to release its Q1 2026 results after the market closes on Thursday, April 23rd. Analysts expect Edwards Lifesciences to post earnings of $0.7280 per share and revenue of $1.5965 billion for the quarter. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, April 23, 2026 at 5:00 PM ET.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). The firm had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. Edwards Lifesciences’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.59 EPS. On average, analysts expect Edwards Lifesciences to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Edwards Lifesciences Price Performance

EW stock opened at $79.79 on Wednesday. The firm has a market cap of $46.00 billion, a price-to-earnings ratio of 43.60, a PEG ratio of 2.12 and a beta of 0.95. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 12-month low of $69.21 and a 12-month high of $87.89. The company’s fifty day simple moving average is $81.43 and its 200 day simple moving average is $82.18.

Wall Street Analyst Weigh In

EW has been the topic of several recent analyst reports. Evercore restated an “outperform” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a report on Monday, January 5th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, January 21st. Stifel Nicolaus set a $110.00 target price on shares of Edwards Lifesciences and gave the company a “buy” rating in a report on Tuesday, January 20th. Robert W. Baird set a $90.00 target price on shares of Edwards Lifesciences in a report on Monday, January 12th. Finally, Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a report on Wednesday, April 1st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average target price of $95.74.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the sale, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at approximately $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction on Monday, April 6th. The shares were sold at an average price of $80.98, for a total transaction of $82,518.62. Following the completion of the sale, the vice president directly owned 33,934 shares of the company’s stock, valued at approximately $2,747,975.32. This trade represents a 2.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 86,058 shares of company stock valued at $7,118,636. Corporate insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the third quarter worth about $25,000. Kemnay Advisory Services Inc. bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $27,000. Rakuten Securities Inc. increased its position in shares of Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares in the last quarter. Kelleher Financial Advisors bought a new stake in shares of Edwards Lifesciences during the third quarter worth about $50,000. Finally, Chapman Financial Group LLC bought a new stake in shares of Edwards Lifesciences during the second quarter worth about $63,000. 79.46% of the stock is owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.